Legend Biotech Corp (LEGN) stock
LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.11+0.12 (+0.75%)
Close on Nov 17, 2026Market cap $2.98BP/E –Yield –
Legend Biotech r&d expenses
Research and development expenses are spending on new products and technology.
Legend Biotech's R&D Expenses for the twelve months ending Jun 30, 2026 was $396.17M, down 1.0% year over year. For fiscal 2025 it was $414.70M, up 0.3% from the year before. The highest annual figure on record is $414.70M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $414.70M | +0.3% |
| FY2024 | Dec 31, 2024 | $413.50M | +8.2% |
| FY2023 | Dec 31, 2023 | $382.20M | +13.9% |
| FY2022 | Dec 31, 2022 | $335.65M | +7.1% |
| FY2021 | Dec 31, 2021 | $313.35M | +35.0% |
| FY2020 | Dec 31, 2020 | $232.16M | +43.4% |
| FY2019 | Dec 31, 2019 | $161.94M | +167.1% |
| FY2018 | Dec 31, 2018 | $60.64M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $96.00M | -2.3% |
| Q1 FY2026 | Mar 31, 2026 | $85.70M | -15.9% |
| Q4 FY2025 | Dec 31, 2025 | $101.33M | -2.9% |
| Q3 FY2025 | Sep 30, 2025 | $113.15M | +18.5% |
| Q2 FY2025 | Jun 30, 2025 | $98.30M | -12.7% |
| Q1 FY2025 | Mar 31, 2025 | $101.90M | +0.9% |
| Q4 FY2024 | Dec 31, 2024 | $104.39M | -1.2% |
| Q3 FY2024 | Sep 30, 2024 | $95.52M | -0.3% |
| Q2 FY2024 | Jun 30, 2024 | $112.63M | +17.6% |
| Q1 FY2024 | Mar 31, 2024 | $100.96M | +18.9% |
| Q4 FY2023 | Dec 31, 2023 | $105.67M | +30.8% |
| Q3 FY2023 | Sep 30, 2023 | $95.86M | -8.3% |
| Q2 FY2023 | Jun 30, 2023 | $95.79M | – |
| Q1 FY2023 | Mar 31, 2023 | $84.89M | – |
| Q4 FY2022 | Dec 31, 2022 | $80.76M | – |
| Q3 FY2022 | Sep 30, 2022 | $104.52M | – |
See a number that looks wrong?